<DOC>
	<DOC>NCT01204710</DOC>
	<brief_summary>This is a study evaluating the safety and efficacy of the monoclonal antibody IMC-3G3 plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.</brief_summary>
	<brief_title>A Study of IMC-3G3 in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>histologicallyconfirmed adenocarcinoma of the prostate radiographic evidence of metastatic prostate cancer (stage M1 or D2) has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of &lt; 50 ng/mL has had disease progression or intolerance on docetaxelbased therapy PSA ≥ 10 ng/mL all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to ≤ Grade 1, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.02 patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 02 adequate hematologic function adequate hepatic function adequate renal function urinary protein is ≤ 1 on dipstick or routine analysis life expectancy of more than 3 months fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study signed Informed Consent document concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms The patient has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease prior therapy with mitoxantrone for advanced prostate cancer The patient has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is ≥ 10% below the lower limit of normal institutional range history of prior treatment with other agents that directly inhibit PDGF or plateletderived growth factor receptors known allergy to any of the treatment components: IMC 3G3, mitoxantrone, and/or prednisone radiotherapy within 21 days prior to first dose of IMC3G3 any investigational therapy within 30 days of randomization is receiving corticosteroids at a dose &gt; 5 mg prednisone orally (PO) 2 times per day (BID) or equivalent received prior strontium89, rhenium186, rhenium188, or samarium153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders known or suspected brain or leptomeningeal metastases known human immunodeficiency virus infection or acquired immunodeficiency syndromerelated illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>